Cordycepin preparation as well as preparation method and application thereof

Through the synergistic effects of Cordycepsin, rhodiola and Gastrodiatin, the problems of large side effects and poor efficacy in the treatment of diabetes complications were solved, and the kidney, liver, testicle and retinal complications in patients with type II diabetes were significantly improved, providing A safe and efficient treatment plan.

CN118948876APending Publication Date: 2024-11-15NANJING SHENG MING YUAN HEALTHY TECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310872356.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-07-17
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The prior art has problems of large side effects and poor efficacy in treating diabetes and its complications, especially for type II diabetes and its associated complications of kidney, liver, testicle and retinal.

Method used

A preparation consisting of Cordyceps, Rhodiola and Gastrodiatin is used to inhibit sugar-induced insulin release through the synergistic action of different components, protect pancreatic beta cells, regulate insulin concentration, and improve complications of diabetes.

Benefits of technology

This preparation significantly lowers blood sugar levels in diabetic rats, improves complication symptoms in kidneys, liver, testicles and retina, reduces oxidative stress damage, improves the quality of life of patients, and avoids traditional drugs due to the natural ingredients. Significant side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118948876A_ABST
    Figure CN118948876A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of natural medicines, and particularly relates to a cordycepin preparation as well as a preparation method and application thereof. The cordycepin composition is prepared from the following components in parts by weight: 1-80 parts of cordycepin; 1 to 100 parts of salidroside; and 1 to 100 parts of gastrodin. Preferably, the composition is prepared from the following components in parts by weight: 10 to 40 parts of cordycepin; 40 to 80 parts of salidroside; and 40 to 80 parts of gastrodin. Compared with traditional medicines for treating diabetes and complications thereof, the cordycepin preparation has the advantages that the components belong to natural extracts and have no obvious side effects on human bodies, the human bodies can normally metabolize, and the problems that in the prior art, no specific medicine is provided for type II diabetes, and existing medicines are large in toxic and side effects can be effectively solved; according to the present invention, the preliminary drug effect research on the diabetic rat kidney complication, the liver complication, the testis injury complication and the retinal injury complication is performed so as to prevent and intervene the type II diabetes mellitus and the complication thereof, such that the positive significance is provided for the treatment of the diabetic complication.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of natural medicines, and specifically relates to a cordycepin preparation and a preparation method and application thereof. Background Art

[0002] Diabetes is a metabolic disease characterized by chronic hyperglycemia caused by a variety of reasons, such as insufficient insulin secretion or defective insulin function. It is mainly manifested by absolute or relative lack of insulin and reduced sensitivity of target cells to insulin. In recent years, the incidence of diabetes has increased dramatically, seriously damaging the physical and mental health of patients and placing a huge burden on the global health system. Diabetes is a chronic progressive disease. Long-term high blood sugar levels can cause chronic damage and dysfunction of various tissues of the body, especially the kidneys, heart, eyes and nerves, leading to a series of complications. At present, the use of therapeutic insulin and oral hypoglycemic drugs is the main method to effectively control the blood sugar level of diabetic patients. However, long-term use of insulin and hypoglycemic drugs can cause side effects to varying degrees.

[0003] Cordycepin, also known as 3′-deoxyadenosine, is an adenosine derivative composed of adenine and deoxypentose. Its structure is very similar to adenosine, so cordycepin is considered to be a very effective biologically active ingredient. In addition, cordycepin has been widely used in Eastern countries as a traditional Chinese medicine and health food. Modern pharmacological research has shown that cordycepin has a wide range of physiological function regulation effects such as the immune system, nervous system, motor system, and endocrine system, so it has important clinical applications and potential development value. Studies have shown that cordycepin can enhance the activity of kidney antioxidant enzymes, improve glomerular filtration, and reduce the oxidative damage to the kidney caused by hyperglycemia; it can inhibit the nuclear transfer and accumulation of Smad2 / 3 in rat kidney fibroblasts (NRK-49F cells) induced by TGF-β1, reduce the downstream synthesis of α-SMA and fibronectin, and have an anti-renal fibrosis effect; it can antagonize high glucose-induced epithelial cell transdifferentiation and reduce the excessive accumulation of extracellular matrix (ECM); cordycepin can significantly inhibit the proliferation of mesangial cells and has a good effect on primary kidney disease. It also has an effect on secondary kidney disease by reducing glomerular filtration and glomerular hypertrophy caused by hyperglycemia, and can reduce the damage of oxidative stress to the kidney in diabetic patients and improve patients' azotemia. As early as 2011, Huang et al. observed that cordycepin can stimulate the PKA-cAMP signaling pathway through adenosine receptors, induce StAR protein expression, promote steroid synthesis, and thus increase the testosterone content in plasma. Recently, Kim et al. also found that cordycepin can increase the expression of mTORC1 in aged rats, promote histone deacetylation, and increase the expression of sperm production-related proteins and mRNA, ultimately improving the sperm motility of aged rats.

[0004] Salidroside is a phenylethanol compound extracted from plants of the Crassulaceae family and the genus Rhodiola. It is also the main biologically active component of Rhodiola rosea. It has multiple pharmacological effects such as anti-inflammatory, anti-tumor, regulating the balance of oxidation / antioxidation systems, enhancing immune function, regulating glucose and lipid metabolism and neuroprotection. It also has a significant therapeutic effect on various complications of diabetes. Studies have found that salidroside can inhibit the expression of VEGF and glial fibrillary acid protein GFAP in retinal tissue, thereby improving the ocular hemorheology and hemodynamics of diabetic retinopathy, and can effectively reduce retinal cell apoptosis; it can reduce the liver index of diabetic rats, significantly reduce the activity of serum transaminases (ALT, AST) and alkaline phosphatase (ALP) in rats, and significantly reduce the content of malondialdehyde (MDA) in liver tissue, and increase the activity of superoxide dismutase (SOD) and catalase (CAT), suggesting that the protective mechanism of salidroside on the liver of diabetic rats may be related to its improvement of antioxidant enzyme activity and inhibition of oxidative stress damage.

[0005] Gastrodin is an extract from the rhizome of the plant Gastrodia elata. It was first isolated by the Kunming Institute of Botany, Chinese Academy of Sciences in 1979. In 1980, the Kunming Institute of Botany completed the chemical synthesis of gastrodin. The chemical name of gastrodin is 4-hydroxymethylphenyl-β-D-pyranoglucoside, and its molecular formula is C 13 H 18 O7, Gastrodin has anti-inflammatory, antioxidant and anti-apoptotic effects. It can cross the blood-brain barrier and be fully and rapidly absorbed in the intestine to exert analgesic, sedative, hypnotic, anticonvulsant and anti-neurodegeneration effects. It is currently widely used to treat neurasthenia, neurasthenia syndrome, traumatic brain syndrome, vertigo and sudden deafness. In recent years, domestic and foreign studies have shown that the natural drug gastrodin plays an important role in improving diabetes and its complications. It can improve the adverse internal environment caused by diabetes through a variety of biological pathways. It is a promising drug for the prevention and treatment of diabetes and its complications, and has important clinical research and application value. Summary of the invention

[0006] The technical problem to be solved by the present invention is to provide a cordycepin preparation in view of the deficiencies in the prior art.

[0007] Furthermore, the technical problem to be solved by the present invention is to provide a method for preparing the above cordycepin preparation.

[0008] Furthermore, the technical problem to be solved by the present invention is to provide the application of the cordycepin preparation.

[0009] In order to solve the above technical problems, the technical solution adopted by the present invention is as follows:

[0010] In order to solve the above-mentioned first technical problem, the present invention discloses a cordycepin preparation, which is composed of the following components in parts by weight:

[0011] 1-80 parts of cordycepin;

[0012] Salidroside 1-100 parts;

[0013] 1-100 parts of gastrodin.

[0014] In some embodiments, preferably, the cordycepin preparation is composed of the following components in parts by weight:

[0015] 10-40 parts of cordycepin;

[0016] Salidroside 40-80 parts;

[0017] 40-80 parts of gastrodin.

[0018] In some embodiments, it is further preferred that the composition is composed of the following components in parts by weight:

[0019] Cordycepin 20 parts;

[0020] Salidroside 60 parts;

[0021] 60 parts of gastrodin.

[0022] In some embodiments, it is further preferred that the composition is composed of the following components in parts by weight:

[0023] Cordycepin 20mg;

[0024] Salidroside 60mg;

[0025] Gastrodin 60mg.

[0026] In some embodiments, the cordycepin has a purity greater than 90%; the mass content of cordyceps polysaccharides in the cordycepin is greater than 6%.

[0027] In some embodiments, the salidroside has a purity greater than 98%.

[0028] In some embodiments, the gastrodin has a purity greater than 98%.

[0029] The cordycepin is extracted from wild Cordyceps militaris and / or artificially cultivated Cordyceps sinensis.

[0030] In some embodiments, the cordycepin preparation is in the form of any one of powder, capsule, pill, granule, tablet and oral liquid preparation.

[0031] In order to solve the above-mentioned second technical problem, the present invention further discloses a method for preparing the above-mentioned cordycepin preparation, wherein cordycepin, salidroside and gastrodin are mixed, one or more pharmaceutically acceptable excipients are added, and the cordycepin preparation is prepared by a conventional preparation method of a pharmaceutical preparation.

[0032] The use of the above cordycepin preparation in the preparation of products for improving complications of type 2 diabetes is also within the protection scope of the present invention.

[0033] Specifically, the product is any one of functional food, medicine and health care product.

[0034] Wherein, the above purity and content are all mass percentages.

[0035] Idea of ​​the invention: Cordycepin can enhance the activity of kidney antioxidant enzymes, improve glomerular filtration, and reduce the oxidative damage to the kidneys caused by hyperglycemia; it can significantly inhibit the proliferation of mesangial cells and has a good therapeutic effect on primary kidney diseases; it also has an effect on secondary kidney diseases by reducing glomerular filtration and glomerular hypertrophy caused by hyperglycemia, and can reduce the damage to the kidneys caused by oxidative stress in diabetic patients and improve patients' azotemia.

[0036] Salidroside can protect pancreatic β cells and lower blood sugar by inhibiting the expression of interleukin 1β (IL-1β), an inflammatory factor of β cells, under high glucose culture conditions. It can effectively improve the oxidative stress state of diabetic model animals, and has an improvement effect on blood sugar, renal mass, serum creatinine, and urine albumin / urine creatinine. In vitro cell experiments have confirmed that the effect of salidroside on the treatment of diabetic complications is related to its ability to inhibit albumin transcytosis caused by hyperglycemia, and the dual effects of antioxidant effect and activation of AMPK may be its main molecular mechanism. Studies have shown that salidroside may help alleviate diabetic nephropathy complications by activating Akt / glycogen synthase kinase β (glycogen synthase kinase 3β, GSK3β) signaling in renal tissue; and improve the arrangement and morphology of rat retinal cells by regulating the PI3K / Akt pathway, prevent the reduction of the number of retinal inner nuclear layer cells and retinal ganglion cells in diabetic retinopathy, and maintain the function of retinal Müller cells in rats with diabetic retinopathy; it can also upregulate the expression of GLAST and GS, and inhibit the apoptosis of Müller cells induced by high glucose.

[0037] Gastrodin has a biphasic regulatory effect on the secretion of insulin in the body. On the one hand, in the state of hyperinsulinemia and insulin resistance induced by high-fat diet, gastrodin can reduce serum insulin concentration and insulin resistance index (IRI) and increase insulin sensitivity index (ISI); on the other hand, in rat insulinoma cells INS-1 cultured in vitro, gastrodin treatment can significantly stimulate insulin release and antagonize STZ-induced INS-1 cell damage and reduced insulin secretion. Gastrodin also has a good antioxidant effect in the treatment of DM. In the STZ-induced Kunming mouse DM model, gastrodin gavage can significantly increase the activity of SOD in animal serum and reduce the content of MDA. In INS-1 cells, gastrodin can inhibit STS-induced cellular oxidative stress, significantly increase T-AOC and significantly reduce MDA, thereby playing a cytoprotective role; the number of retinal ganglion cells in diabetic rats treated with gastrodin and its derivatives increased significantly, the morphology became more regular, and the damage was reduced, which may be one of the protective mechanisms of gastrodin against retinal ganglion cell damage caused by diabetes. In summary, gastrodin can improve the activity of retinal cells and reduce their damage, and may become an effective drug for protecting diabetic optic nerves and preventing and treating DR.

[0038] The cordycepin, salidroside and gastrodin in the cordycepin preparation of the present invention complement each other. Cordycepin can inhibit the release of insulin induced by sugar, salidroside can protect pancreatic beta cells, and gastrodin regulates the concentration of insulin. The three components play a role in lowering blood sugar from different levels, overcome the limitations of a single component, work synergistically together, and further improve the improvement level of diabetes and its complications.

[0039] Beneficial effects:

[0040] (1) Compared with traditional drugs for treating diabetes and its complications, the ingredients in the cordycepin preparation of the present invention are all natural extracts, have no obvious side effects on the human body, and can be metabolized normally by the human body. This can effectively solve the problem that there is no specific drug for type II diabetes in the prior art and that existing drugs have large toxic and side effects. The present invention prevents and intervenes in type II diabetes and its complications through preliminary efficacy studies on kidney complications, liver complications, testicular damage complications, and retinal damage complications in diabetic rats.

[0041] (2) The cordycepin preparation of the present invention has a significant improvement effect on the kidney complications, liver complications, testicular damage complications and retinal damage complications of diabetic rats, and can greatly improve the related symptoms of complications, which has a positive significance for the treatment of diabetic complications. BRIEF DESCRIPTION OF THE DRAWINGS

[0042] The present invention will be further described in detail below in conjunction with the accompanying drawings and specific embodiments, and the above and / or other advantages of the present invention will become more clear.

[0043] Figure 1 Statistical diagram of renal index of experimental mice; ###P<0.001, **P<0.01, ***P<0.001, # indicates compared with the normal control group (KB), and * indicates compared with the diabetic model control group (M).

[0044] Figure 2 The statistical graphs are of urine volume, urine protein, urine creatinine and urea nitrogen levels of mice at week 16; ##P<0.01, ###P<0.001, *P<0.05, **P<0.01, # indicates compared with the normal control group, and * indicates compared with the model control group.

[0045] Figure 3 The statistical chart of blood creatinine and blood urea nitrogen levels in mice at week 16; #P<0.05, ###P<0.001, *P<0.05, **P<0.01, # indicates compared with the normal control group, and * indicates compared with the model control group.

[0046] Figure 4 This is the HE staining picture of the renal tissue morphology of experimental mice, among which, Figure 4 (A) Normal control group, Figure 4 (B) Diabetes model control group, Figure 4 (C) Cordycepin preparation group 1, Figure 4 (D) Cordycepin preparation 2 groups, Figure 4 (E) Three groups of cordycepin preparations, Figure 4 (F) Four groups of cordycepin preparations.

[0047] Figure 5 This is the Masson staining result of the experimental mouse kidney tissue; Figure 5 (A) Normal control group, Figure 5 (B) Diabetes model control group, Figure 5 (C) Cordycepin preparation group 1, Figure 5 (D) Cordycepin preparation 2 groups, Figure 5 (E) Three groups of cordycepin preparations, Figure 5 (F) Four groups of cordycepin preparations.

[0048] Figure 6 This is the result of PAS staining of the renal tissue of experimental mice; Figure 6 (A) Normal control group, Figure 6 (B) Diabetes model control group, Figure 6 (C) Cordycepin preparation group 1, Figure 6 (D) Cordycepin preparation 2 groups, Figure 6(E) Three groups of cordycepin preparations, Figure 6 (F) Four groups of cordycepin preparations.

[0049] Figure 7 Statistical graph of liver index of experimental mice; ###P<0.001, ***P<0.001, # indicates compared with the normal control group (KB), and * indicates compared with the diabetic model control group.

[0050] Figure 8 This is a graph showing the test results of liver biochemical indicators in experimental mice; among them, #P<0.05, ##P<0.01, ###P<0.001, *P<0.05, **P<0.01, ***P<0.001, # indicates compared with the normal control group, and * indicates compared with the diabetic model control group.

[0051] Fig. 9 This is the HE staining picture of the liver tissue morphology of experimental mice; Fig. 9 (A) Normal control group, Fig. 9 (B) Diabetes model control group, Fig. 9 (C) Cordycepin preparation group 1, Fig. 9 (D) Cordycepin preparation 2 groups, Fig. 9 (E) Three groups of cordycepin preparations, Fig. 9 (F) Four groups of cordycepin preparations.

[0052] Fig.10 This is the MASSON staining picture of the liver tissue morphology of experimental mice; Fig.10 (A) Normal control group, Fig.10 (B) Diabetes model control group, Fig.10 (C) Cordycepin preparation group 1, Fig.10 (D) Cordycepin preparation 2 groups, Fig.10 (E) Three groups of cordycepin preparations, Fig.10 (F) Four groups of cordycepin preparations.

[0053] Fig.11 This is the Oil Red O staining picture of the liver tissue morphology of experimental mice; Fig.11 (A) Normal control group, Fig.11 (B) Diabetes model control group, Fig.11 (C) Cordycepin preparation group 1, Fig.11 (D) Cordycepin preparation 2 groups, Fig.11 (E) Three groups of cordycepin preparations, Fig.11 (F) Four groups of cordycepin preparations.

[0054] Fig.12 This is the PAS staining picture of the liver tissue of the experimental mouse; Fig.12 (A) Normal control group, Fig.12 (B) Diabetes model control group, Fig.12 (C) Cordycepin preparation group 1, Fig.12 (D) Cordycepin preparation 2 groups, Fig.12 (E) Three groups of cordycepin preparations, Fig.12 (F) Four groups of cordycepin preparations.

[0055] Fig.13 This is the Sirius red staining picture of the liver tissue of the experimental mouse; Fig.13 (A) Normal control group, Fig.13 (B) Diabetes model control group, Fig.13 (C) Cordycepin preparation group 1, Fig.13 (D) Cordycepin preparation 2 groups, Fig.13 (E) Three groups of cordycepin preparations, Fig.13 (F) Four groups of cordycepin preparations.

[0056] Fig.14 Statistical graph of testicular index; #P<0.05, *P<0.05, # indicates compared with the normal control group, and * indicates compared with the diabetic model control group.

[0057] Fig.15 This is a sperm staining diagram; Fig.15 (A) Normal control group, Fig.15 (B) Diabetes model control group, Fig.15 (C) Cordycepin preparation group 1, Fig.15 (D) Cordycepin preparation 2 groups, Fig.15 (E) Three groups of cordycepin preparations, Fig.15 (F) Four groups of cordycepin preparations.

[0058] Fig.16 The sperm count statistics are shown in Figure 2; ###P<0.001, *P<0.05, **P<0.01, # indicates compared with the normal control group, and * indicates compared with the diabetic model control group.

[0059] Fig.17 This is the H&E staining picture of the testicular tissue morphology of experimental mice; Fig.17 (A) Normal control group, Fig.17 (B) Diabetes model control group, Fig.17 (C) Cordycepin preparation group 1, Fig.17 (D) Cordycepin preparation 2 groups, Fig.17 (E) Three groups of cordycepin preparations, Fig.17 (F) Four groups of cordycepin preparations.

[0060] Fig.18 This is the PAS staining picture of the testicular tissue morphology of experimental mice; Fig.18 (A) Normal control group, Fig.18 (B) Diabetes model control group, Fig.18 (C) Cordycepin preparation group 1, Fig.18 (D) Cordycepin preparation group 2, Fig.18 (E) Cordycepin preparation group 3, Fig.18 (F) Cordycepin preparation group 4.

[0061] Fig.19 are H&E staining diagrams of the retinas of experimental mice; among them, Fig.19 (A) Normal control group, Fig.19 (B) Diabetic model control group, Fig.19 (C) Cordycepin preparation group 1, Fig.19 (D) Cordycepin preparation group 2, Fig.19 (E) Cordycepin preparation group 3, Fig.19 (F) Cordycepin preparation group 4. Detailed implementation method

[0062] In the following embodiments, the experimental methods are all conventional methods unless otherwise specified; the reagents and materials can be obtained from commercial channels unless otherwise specified.

[0063] In the following embodiments, the purity of cordycepin used is greater than 90%, and the mass content of cordycepian polysaccharide in cordycepin is greater than 6%.

[0064] The salidroside used in the embodiments of the present invention has a purity greater than 98%.

[0065] The gastrodin used in the embodiments of the present invention has a purity greater than 98%.

[0066] The mice used in the embodiments of the present invention are SPF-grade male C57 / BL mice, with a body weight of 25 - 30 g, purchased from Qinglongshan Animal Breeding Farm in Jiangning District, Nanjing (animal certificate number: SCXK(Yu)2020 - 0005).

[0067] The streptozotocin used in the embodiments of the present invention has a purity greater than 98%, is sub-packed by sigma, and is purchased from Nanjing Thermo Fisher Biological Reagent Company.

[0068] The citric acid - sodium citrate buffer solution used in the embodiments of the present invention is 0.1 mol / L, pH = 4.5.

[0069] In this embodiment Figure 1 、 Figure 2 、 Figure 3 、 Figure 7 、 Figure 8 、 Fig.14 、 Fig.16 The KB marked is the normal control group or blank group in the literal part of the embodiment; Figure 1 、 Figure 2 、 Figure 3 、 Figure 7 , Figure 8 , Fig.14 , Fig.16 The M in the figure refers to the model control group in the text of the embodiment; Figure 1 , Figure 2 , Figure 3 , Figure 7 , Figure 8 , Fig.14 , Fig.16 The cordycepin preparation group 1 marked in the text part is the cordycepin preparation group 1 in the text part of the examples; Figure 1 , Figure 2 , Figure 3 , Figure 7 , Figure 8 , Fig.14 , Fig.16 The cordycepin preparation group 2 marked in the text part is the cordycepin preparation group 2 in the text part of the examples; Figure 1 , Figure 2 , Figure 3 , Figure 7 , Figure 8 , Fig.14 , Fig.16 The cordycepin preparation group 3 marked in the text part is the cordycepin preparation group 3 in the text part of the examples; Figure 1 , Figure 2 , Figure 3 , Figure 7 , Figure 8 , Fig.14 , Fig.16 The cordycepin preparation group 4 marked in the figure is the cordycepin preparation group 4 in the text part of the examples.

[0070] Example 1: Preparation of Cordycepin Preparation 1

[0071] Weigh 10 mg of cordycepin, 60 mg of salidroside, and 60 mg of gastrodin, dissolve in 10 mL of sterile water, stir evenly and fully dissolve.

[0072] Comparative Example 1: Preparation of Formulation A

[0073] Weigh 10 mg of cordycepin and 60 mg of salidroside, dissolve in 10 mL of sterile water, stir evenly and fully dissolve.

[0074] Comparative Example 2: Preparation of Formulation B

[0075] Weigh 60 mg of salidroside and 60 mg of gastrodin, dissolve them in 10 mL of sterile water, stir evenly and fully dissolve.

[0076] Comparative Example 3: Preparation of Formulation C

[0077] Weigh 10 mg of cordycepin and 60 mg of gastrodin, dissolve in 10 mL of sterile water, stir evenly and fully dissolve.

[0078] Comparative Example 4: Preparation of Formulation D

[0079] Weigh 10 mg of cordycepin, 60 mg of salidroside, 60 mg of gastrodin, and 60 mg of moutan bark, dissolve in 10 mL of sterile water, stir evenly and fully dissolve to obtain the product.

[0080] Example 2: Preparation of Cordycepin Preparation 2

[0081] Weigh 20 mg of cordycepin, 60 mg of salidroside, and 60 mg of gastrodin, dissolve in 10 mL of sterile water, stir evenly and fully dissolve.

[0082] Example 3: Preparation of Cordycepin Preparation 3

[0083] Weigh 40 mg of cordycepin, 60 mg of salidroside, and 60 mg of gastrodin, dissolve in 10 mL of sterile water, stir evenly and fully dissolve to obtain the product.

[0084] Example 4: Preparation of Cordycepin Preparation 4

[0085] Weigh 20 mg of cordycepin, 40 mg of salidroside, and 60 mg of gastrodin, dissolve in 10 mL of sterile water, stir evenly and fully dissolve.

[0086] Example 5: Effects of different cordycepin preparations on blood glucose in type 2 diabetic mice

[0087] 1. Establishment of type 2 diabetes mouse model

[0088] Establishment of type 2 diabetes pathological model: SPF male C57 / BL mice (mouse weight 25-30g) were fed a high-fat diet for 4 weeks (starting from the fifth week), and then intraperitoneally injected with streptozotocin solution (the daily dose of streptozotocin was 50mg / kg, and the solvent in the solution was citric acid-sodium citrate buffer, 0.1mol / L, pH=4.5) for 5 consecutive days, once a day; blood glucose was measured on the fourth day after the end of streptozotocin administration, and if the fasting blood glucose was greater than 16.7mmol / L, the type 2 diabetes model was considered to be formed; mice whose blood glucose did not reach the standard were continuously injected with streptozotocin for three days, and their blood glucose was measured again. After the model was established, drug treatment began and continued for twelve weeks.

[0089] The animal breeding environment of the present invention is: SPF grade, room temperature is 20.0°C-22.5°C, relative humidity is 54.4%RH-68.4%RH, group cage breeding, 8 animals / cage, 48 animals in total.

[0090] The 8 healthy mice in the blank group were kept in a group cage in an SPF grade environment with a room temperature of 20.0°C to 22.5°C and a relative humidity of 54.4%RH to 68.4%RH.

[0091] 2. Grouping and Dosing of Mice

[0092] Grouping: The 48 modeling mice were randomly divided into 6 groups, with 8 mice in each group, namely, model control group, cordycepin preparation group 1, comparative example group 1, comparative example group 2, comparative example group 3, and comparative example group 4; in addition, a blank group was included, which consisted of 8 healthy mice.

[0093] Administration: blank group: gavage of 0.5 mL citric acid-sodium citrate buffer (0.1 mol / L, pH=4.5) every other day; model control group: gavage of 0.5 mL citric acid-sodium citrate buffer (0.1 mol / L, pH=4.5) every other day; cordycepin preparation group 1, comparative example group 1, comparative example group 2, comparative example group 3 and comparative example group 4 took cordycepin preparation 1 (prepared in Example 1), preparation A (prepared in comparative example 1), preparation B (prepared in comparative example 2), preparation C (prepared in comparative example 3), preparation D (prepared in comparative example 4), respectively; the dosage is calculated in terms of cordycepin, and the dosage of cordycepin is 500 μg / time / rat, once a day, and gavage is administered every other day.

[0094] 3. Effects of different cordycepin preparations on blood glucose in type 2 diabetic mice

[0095] The blood glucose measurement results of the experimental mice are shown in Table 1. The experimental results show that after the model group mice were given different cordycepin preparations for intervention, the blood glucose levels of the cordycepin preparation intervention group were significantly reduced compared with the type 2 diabetes model control group, and the effect of cordycepin preparation 1 prepared in Example 1 after administration was significantly better than that of other control groups. The experimental results show that the cordycepin preparation containing only three ingredients, cordycepin, salidroside and gastrodin, has better effect.

[0096] Table 1 Blood glucose level data of experimental mice

[0097]

[0098]

[0099] Example 6: Detection indexes and detection methods of cordycepin preparations with different weight portions on complications of type 2 diabetic mice

[0100] 1. Organ index

[0101] Before being killed, mice were fasted but not watered. Eyeballs of mice in each group were removed to collect blood, which was centrifuged at 4°C, 1500 rpm for 10 minutes. Serum was collected and stored at -20°C for later use. Mice were killed by cervical dislocation, and the liver, kidney, and testicle were removed, accurately weighed, and the organ index was calculated. The calculation formula of the organ index is as follows:

[0102] Organ index (%) = organ weight (g) / tibia length × 100%.

[0103] 2. Diabetic nephropathy detection indicators

[0104] 1) Urine biochemistry

[0105] Urine collection: Before killing, fast but not water, collect urine within 24 hours in metabolic cage and measure the volume;

[0106] Urine protein: urine protein (BCA) detection kit (Nanjing Jiancheng);

[0107] Urine creatinine: Urine creatinine (UCR) detection kit (Nanjing Jiancheng);

[0108] Urea nitrogen: Urea nitrogen (BUN) test kit (urease method), (Nanjing Jiancheng, C013-2-1).

[0109] 2) Blood biochemistry

[0110] ① Blood creatinine: Creatinine (Cr) test kit (chemical method, protein removal) colorimetric method, (Nanjing Jiancheng, C011-1-1).

[0111] ② Blood urea nitrogen: urea nitrogen (BUN) test kit (urease method), (Nanjing Jiancheng, C013-2-1).

[0112] 3) Histomorphology

[0113] ①HE staining

[0114] The kidney tissue fixed with a 4% paraformaldehyde solution was prepared into 5 μm paraffin sections according to the steps of paraffin section preparation, rehydration, dehydration, permeabilization, and sealing. The kidney sections were then baked at 60°C for 30 minutes to melt the paraffin, and then dewaxed in xylene for a total of three times, each time for 10 minutes. The dewaxed kidney sections were placed in anhydrous ethanol, 95% alcohol by volume, 85% alcohol by volume, 75% alcohol by volume, and 50% alcohol by volume for 5 minutes each for rehydration. Then, the nuclei were stained with hematoxylin solution for 1 to 2 minutes, differentiated with 1% hydrochloric acid ethanol solution by volume for 5 to 10 seconds, and rinsed with tap water to return to blue. Dehydrated with gradient alcohol (volume fraction of 50%, volume fraction of 75%, volume fraction of 85%, volume fraction of 95%, 100%), and stained with eosin solution for 15 min (under dark conditions), and then dehydrated in anhydrous ethanol three times, each time for 5 min. Finally, xylene was used for permeabilization, a total of 2 times, each time for 5 min. The obtained kidney sections were sealed with neutral resin and placed under a microscope (400X) for observation and photography to evaluate the effect of cordycepin preparations on kidney tissue structure.

[0115] ②Masson staining

[0116] The preparation and rehydration methods of paraffin sections of kidneys were the same as those in "①HE staining". The rehydrated kidney sections were placed in Weigert iron hematoxylin solution for staining for 7 minutes, followed by differentiation and washing, and then immersion in Masson blue solution. After washing, they were stained with Ponceau fuchsin for 7 minutes, and then immersed in a 2% glacial acetic acid aqueous solution for 3 minutes, followed by differentiation with a 1% phosphomolybdic acid aqueous solution for 3 minutes, and then stained with aniline blue for 2 minutes, and immersed in a 2% glacial acetic acid aqueous solution for 3 minutes; finally, conventional dehydration, permeabilization and sealing were performed in the same way as in "①HE staining". The obtained kidney sections were placed under a microscope (400X) and photographed to evaluate the effects of cordycepin preparations on the kidneys.

[0117] ③PAS staining

[0118] The preparation and rehydration methods of kidney paraffin sections were the same as those in "①HE staining". A 10 g / L periodic acid aqueous solution was added to the kidney paraffin sections for 15 minutes, followed by washing with distilled water, adding Schiff stain for 15 minutes, and washing with distilled water again; then the nuclei were stained with hematoxylin, and the sections were blued with tap water; finally, the sections were blued for 3 minutes with Scott stain, and then routinely dehydrated, permeabilized, and sealed as in "①HE staining". The obtained sections were observed and photographed under a 400X fiberscope to evaluate the effects of cordycepin preparations on the kidneys.

[0119] 3. Detection of diabetic liver disease related indicators

[0120] 1) Biochemical indicators

[0121] Liver function index

[0122] ① Alanine aminotransferase / ALT: Nanjing Jiancheng, C009-1-1;

[0123] ②Aspartate aminotransferase / AST: Nanjing Jiancheng, C010-1-1.

[0124] Liver lipid metabolism markers

[0125] ① Triglyceride (TG): Nanjing Jiancheng, A110-1-1;

[0126] ② Low-density lipoprotein cholesterol (LDL-C): Nanjing Jiancheng, A113-1-1;

[0127] ③ High-density lipoprotein cholesterol (HDL-C): Nanjing Jiancheng, A112-1-1;

[0128] ④Total cholesterol (T-CHO): Nanjing Jiancheng, A111-1-1.

[0129] 2) Histological morphology

[0130] ①HE staining: observe liver tissue damage, the method is the same as "2. Diabetic nephropathy detection indicators 3) Histomorphology ①HE staining".

[0131] ②Masson staining: observe the formation of liver collagen fibers and muscle fibers. The method is the same as that in “2. Diabetic nephropathy detection indicators 3) Tissue morphology ②Masson staining”.

[0132] ③ Sirius red staining

[0133] The preparation and rehydration methods of liver paraffin sections were the same as those in “2. Diabetic nephropathy detection indicators 3) Histomorphology ① HE staining”; the rehydrated liver sections were stained with Sirius red staining solution for 1 hour, rinsed with running water for 10 seconds, rinsed with a 0.5% acetic acid aqueous solution for 20 seconds, and then dehydrated with anhydrous ethanol 3 times, each time for 3 minutes, and transparentized with xylene 2 times, each time for 5 minutes. After dehydration, the sections were sealed with neutral resin, and the obtained liver sections were placed under a microscope (400X) for observation and photography.

[0134] ④ Oil Red O staining

[0135] The slices were immersed in a 60% isopropanol aqueous solution for 2 minutes, washed with ice distilled water for 3 minutes, and added to the modified Oil Red O staining solution (preparation of the modified Oil Red O staining solution: 0.5g Oil Red O, 100mL of 50% ethanol by volume, dissolving Oil Red O in ethanol, and stirring continuously until completely dissolved), and sealed for 10 to 15 minutes. The process was protected from light, and then washed with ice distilled water for 3 minutes, added to a 60% isopropanol aqueous solution and washed slightly to remove the stain for about 10 seconds, added to ice distilled water for washing for 3 minutes, hematoxylin staining solution was used to counterstain the nucleus for 5 minutes, and then washed with ice distilled water for 3 minutes. The slices were dried with filter paper and sealed conventionally. The obtained liver slices were placed under a microscope (400X) and photographed to observe liver fat particles.

[0136] ⑤PAS staining: observe the extracellular matrix deposition, the method is the same as "③PAS staining of tissue morphology in 2. Diabetic nephropathy detection indicators 3)".

[0137] 4. Detection of related indicators of diabetic testicular damage

[0138] 1) Sperm count

[0139] Take 1mL of normal saline and put it in a 1.5mL centrifuge tube and keep it warm at 37℃; cut the epididymis scissors four times, put the cut epididymis in another centrifuge tube, shake and free sperm for 15 minutes; dilute it with 37℃ normal saline to an appropriate multiple, with a total volume of 1mL (20 times for unilateral epididymis, 40 times for bilateral epididymis, depending on the situation); take 10μL to count on a counting plate, and use the rest for smear staining.

[0140] 2) Sperm staining

[0141] Nanjing Jiancheng's sperm rapid staining solution (D029-1) was used. Take 100 μL of the remaining liquid in step "1) sperm counting" and a glass slide, push the glass slide to flatten the liquid and dry it naturally; fix it with 95% ethanol by volume for 2 minutes, air dry it naturally, hydrate it for 1 minute after it is completely dry, and stain it with Harris hematoxylin for 3 minutes; rinse it with tap water for 1 minute to alkalinize it; stain it with Scott solution for 4 minutes; wash it with distilled water for 1 minute, and rinse it with 50%, 70%, 80%, and 95% ethanol by volume for 10 seconds each; stain it with orange G6 solution for 2 minutes; rinse it with 95% ethanol by volume twice; stain it with EA36 solution for 5 minutes; rinse it with 95% ethanol by volume and 100% ethanol by volume twice, each time for 10 seconds; and seal it with xylene.

[0142] 3) Histomorphology

[0143] ①HE staining: observe the testicular tissue morphology, the method is the same as "2. Diabetic nephropathy detection indicators 3) Tissue morphology ①HE staining".

[0144] ②PAS staining: observe the testicular spermatogenic epithelium cycle, the method is the same as "③PAS staining of tissue morphology in 2. Diabetic nephropathy detection indicators 3)".

[0145] 5. Routine indicators of diabetic retinopathy

[0146] HE staining: the method is the same as that in “2. Diabetic nephropathy detection indicators 3) Histomorphology ① HE staining”.

[0147] Example 7: Effects of Cordycepin Preparations of Different Weights on Complications in Type 2 Diabetic Mice

[0148] 1. Establishment of type 2 diabetes mouse model

[0149] Establishment of type 2 diabetes pathological model: SPF male C57 / BL mice (mouse weight 25-30g) were fed a high-fat diet for 4 weeks (starting from the fifth week), and then intraperitoneally injected with streptozotocin solution (the daily dose of streptozotocin was 50mg / kg, and the solvent in the solution was citric acid-sodium citrate buffer, 0.1mol / L, pH=4.5) for 5 consecutive days, once a day; blood glucose was measured on the fourth day after the end of streptozotocin administration, and if the fasting blood glucose was greater than 16.7mmol / L, the type 2 diabetes model was considered to be formed; mice whose blood glucose did not reach the standard were continuously injected with streptozotocin for three days, and their blood glucose was measured again. After the model was established, drug treatment began and continued for twelve weeks.

[0150] The animal breeding environment of the present invention is: SPF grade, room temperature is 20.0℃~22.5℃, relative humidity is 54.4%RH~68.4%RH, group cage breeding, 10 animals / cage, totally 50 animals.

[0151] The 10 healthy mice in the blank group were kept in a group cage in an SPF grade environment with a room temperature of 20.0°C to 22.5°C and a relative humidity of 54.4%RH to 68.4%RH.

[0152] 2. Grouping and Dosing of Mice

[0153] Grouping: The 50 modeling mice were randomly divided into 5 groups, with 10 mice in each group, namely model control group, cordycepin preparation group 1, cordycepin preparation group 2, cordycepin preparation group 3 and cordycepin preparation group 4; in addition, there was also a blank group, which consisted of 10 healthy mice, and the blank group was the normal control group.

[0154] Administration: blank group: gavage with 0.5 mL citric acid-sodium citrate buffer (0.1 mol / L, pH=4.5) every other day; model control group: gavage with 0.5 mL citric acid-sodium citrate buffer (0.1 mol / L, pH=4.5) every other day; cordycepin preparation 1 group, cordycepin preparation 2 group, cordycepin preparation 3 group and cordycepin preparation 4 group took cordycepin preparation 1 (prepared in Example 1), cordycepin preparation 2 (prepared in Example 2), cordycepin preparation 3 (prepared in Example 3) and cordycepin preparation 4 (prepared in Example 4), respectively; the dosage is calculated in terms of cordycepin, and the dosage of cordycepin is 500 μg / time / rat, once a day, and gavage is administered every other day.

[0155] 3. Effects of different weight proportions of cordycepin preparations on renal complications in type 2 diabetic mice

[0156] For specific experimental methods, refer to the experimental methods described in “1. Organ index” and “2. Diabetic nephropathy detection index” of “Example 6”.

[0157] Renal index determination: Figure 1 The results showed that compared with the normal control group (blank group, KB), the renal index of the diabetic model control group (M) was significantly increased (P<0.001); after the model mice were treated with cordycepin preparations, the renal index of cordycepin preparation group 1, cordycepin preparation group 2, cordycepin preparation group 3, and cordycepin preparation group 4 were significantly decreased compared with the model control group, among which the cordycepin preparation group 2 was more obvious, showing better therapeutic effect (P<0.001); the results showed that cordycepin preparations can improve kidney enlargement caused by diabetes.

[0158] Urine biochemistry (urine volume, urine protein, urine creatinine, urea nitrogen) measurement: the test results are as follows Figure 2 As shown in the figure, compared with the normal control group (i.e., blank group, KB), the urine volume and urine protein of the mice in the diabetic model control group (M) were significantly increased (P<0.001), and were significantly reduced after 12 weeks of cordycepin preparation treatment. Among them, cordycepin preparation group 2 and cordycepin preparation group 3 showed better therapeutic effects after administration; at the same time, compared with the normal control group (i.e., blank group, KB), the urine creatinine (P<0.01) and urea nitrogen of the mice in the diabetic model control group (M) were extremely significantly decreased (P<0.001), and the administration of cordycepin preparation group 2 significantly reversed the decrease of urine creatinine and urea nitrogen (P<0.05). After administration of cordycepin preparation group 1, cordycepin preparation group 3 and cordycepin preparation group 4, the levels of urine creatinine and urea nitrogen showed an upward trend, but no significant difference was found.

[0159] Blood biochemistry (serum creatinine, blood urea nitrogen) determination: the results are as follows Figure 3As shown, compared with the normal control group (i.e., blank group, KB), the levels of blood creatinine (P<0.05) and blood urea nitrogen (P<0.001) in the diabetic model control group (M) mice were significantly increased. After 12 weeks of treatment with cordycepin preparations, the four groups significantly reversed the increase of blood creatinine and blood urea nitrogen. After the administration of cordycepin preparations, blood creatinine and blood urea nitrogen showed a downward trend; among them, compared with the model control group (M), the blood urea nitrogen level of cordycepin preparation group 2 showed significant difference after administration (P<0.01); the above results indicate that cordycepin preparations can improve renal dysfunction in type 2 diabetic mice.

[0160] Histomorphological determination: HE staining results are as follows Figure 4 As shown in the figure, the HE staining results of the kidneys of mice in each group showed that the renal tubules and glomeruli of mice in the normal control group (i.e., blank group, KB) were normal in morphology and structure, and no inflammatory cell infiltration occurred; the renal tubules of mice in the diabetic model control group were swollen, vacuolar deformation, some epithelial cells fell off into the tubular cavity, the number of renal tubules decreased, the boundaries were unclear, a large amount of interstitial connective tissue proliferated, the glomeruli were congested and dilated, the glomerular basement membrane was thickened, and inflammatory cell infiltration occurred in the renal tissue; compared with the model group, the glomerular and tubular structures of the cordycepin preparation group were improved to a certain extent, cell shedding decreased, and edema and congestion were alleviated. Among them, the treatment effect of cordycepin preparation group 2 was more obvious. The above experimental results show that cordycepin preparation can improve the renal tissue structure damage caused by diabetes.

[0161] The results of Masson staining of kidneys are as follows Figure 5 As shown in the figure, the normal control group (blank group, KB) mice had normal glomerular and tubular structures and normal collagen expression; the diabetic model control group had obvious collagen accumulation in the glomerular basement membrane and tubular interstitium, and the structure was disordered; the cordycepin preparation groups were able to improve the collagen deposition around the glomerulus and tubular interstitium, and the improvement of cordycepin preparation group 2 was more obvious.

[0162] PAS staining results of kidneys Figure 6 As shown, the renal tissues of mice in the diabetic model control group showed obvious glomerular mesangial proliferation, tubular interstitial fibrosis, and severe glomerular cavitation. The cordycepin preparation group could significantly improve the above symptoms.

[0163] 4. Effects of different weight proportions of cordycepin preparations on liver complications in type 2 diabetic mice

[0164] For specific experimental methods, refer to the experimental methods described in “1. Organ index” and “3. Detection of diabetic liver disease-related indicators” in “Example 6”.

[0165] Liver index determination: Figure 7As shown, compared with the normal control group (i.e., blank control group, KB), the liver index of mice in the diabetic model control group was significantly increased (P<0.001); after the administration of cordycepin preparation, the cordycepin preparation group was significantly downregulated compared with the model control group (P<0.001), showing the same therapeutic effect.

[0166] Biochemical index determination - liver lipid metabolism index determination: Figure 8 The results of biochemical liver function test of mice showed that compared with the normal control group (blank group, KB), the total cholesterol (T-CHO) and triglyceride (TG) indicators of the diabetic model control group (M) mice were significantly upregulated (P<0.001); compared with the model control group, the cordycepin preparation group reversed the upregulation of TG and T-CHO, especially showing a better reversal effect on T-CHO (P<0.001).

[0167] In addition, the results of HDL-C index detection showed that the diabetic model control group (M) was significantly increased compared with the normal control group (blank group, KB) (P<0.05), which was reversed after treatment with cordycepin preparations. Cordycepin preparation group 2 (P<0.05) and cordycepin preparation group 3 (P<0.05) showed better reversal effects, while no regular differences were found in LDL-C.

[0168] Biochemical index determination - liver function index determination: from Figure 8 It can be seen that compared with the normal control group (i.e. blank group, KB), the AST index of mice in the diabetes model control group (M) was upregulated (P<0.01), and the ALT index of mice in the diabetes model control group was more significantly upregulated (P<0.001). After the administration of cordycepin preparations, the AST index decreased, among which cordycepin preparation group 1 showed a significant difference (P<0.05). At the same time, cordycepin preparations showed a better reversal effect on the ALT index, which was extremely significantly decreased (P<0.001), among which cordycepin preparation group 3 had the best effect.

[0169] Histomorphological determination: HE staining Fig. 9 As shown, the H&E staining results showed that the liver structure of mice in the normal control group (i.e., blank group) was intact, binucleate and multinucleate hepatocytes were common, the liver lobule structure was normal and relatively regular, and the cell structure was clear; compared with the normal control group, the liver tissue structure of mice in the diabetic model control group was obviously abnormal, with obvious vacuolation, disordered arrangement of hepatocytes, distorted morphology of most hepatocytes, and fat accumulation in the cytoplasm of some hepatocytes; compared with the model control group, the four cordycepin preparation groups had significantly improved hepatocyte degeneration, distortion and vacuolation.

[0170] Masson staining dyes collagen fibers blue and is the main staining method for determining liver fibrosis. Fig.10This is the result of MASSON staining of the liver. It can be seen from the figure that the hepatic cords of the mice in the normal control group (i.e., blank group) are neatly arranged, the small veins and arterioles in the portal area are normal, and there is no fibrous tissue hyperplasia; compared with the normal control group, the interlobular veins and arteries of the mice in the diabetic model control group were accompanied by obvious connective tissue hyperplasia, and the cordycepin preparation administration in the cordycepin preparation group significantly improved the fibrous tissue hyperplasia and collagen deposition.

[0171] The red position in Oil Red O staining represents the aggregation site of lipids in hepatocytes. The area and depth of red reflect the severity of lipid deposition. Fig.11 As shown, compared with the normal control group (ie, blank group), the microvesicular fatty degeneration of the diabetic model control group mice was significantly increased, and the fatty degeneration was significantly reversed after the four cordycepin preparation groups were given cordycepin preparations.

[0172] PAS staining results of liver Fig.12 As shown in the figure, the liver cell structure of mice in the normal control group (i.e., blank group) was dense and complete, arranged neatly, with occasional vesicular fat droplet vacuoles, and full and uniform PAS staining between cells; compared with the normal control group, the cell morphology of the diabetic model control group was deformed, the arrangement was disordered, a large number of fat vacuoles were seen, and the staining was relatively thin and uneven. After the administration of cordycepin preparations, the cell morphology returned to normal and was densely arranged, and the therapeutic effects of cordycepin preparation group 2 and cordycepin preparation group 3 were more obvious.

[0173] Sirius red staining Fig.13 As shown, from Fig.13 The results of Sirius red staining showed that compared with the normal control group (i.e. blank group), there were a large number of red collagen deposits around the liver tissue veins of the mice in the diabetic model control group. The administration of cordycepin preparation significantly reversed the liver collagen deposition caused by diabetes.

[0174] 5. Effects of different weight proportions of cordycepin preparations on testicular injury complications in type 2 diabetic mice

[0175] Testicular index determination: Fig.14 As shown, the testicular index of mice in the diabetic model control group (M) was significantly decreased compared with that in the blank control group (i.e., blank group, KB), and the testicular index of mice in the four cordycepin preparation-administered groups was significantly increased compared with that in the model control group. The experimental results showed that the cordycepin preparation reversed the testicular atrophy caused by diabetes.

[0176] Sperm staining Fig.15As shown in the figure, the sperm morphology of the normal control group (i.e., blank group) was normal, without abnormal sperm; most of the sperm in the diabetic model control group were abnormal, with abnormal structures such as loss of sperm head and folded tail observed. After administration of cordycepin preparation, most of the sperm morphology returned to normal, with cordycepin preparation 1 group showing the best therapeutic effect; at the same time, Fig.16 As shown, the sperm count of mice in the diabetic model control group (M) was significantly lower than that in the normal control group (i.e., blank group, KB) (P<0.001); compared with the model control group (M), the sperm count of mice in each cordycepin preparation group was significantly increased, and the effect of cordycepin preparation 1 group was better.

[0177] Testicular tissue morphology determination: H&E staining results of mouse testis are as follows Fig.17 As shown in the figure, the testicular tissue structure of the normal control group (i.e., blank group) was clear, the cell layers were very rich, the spermatogenic cells of each layer in the seminiferous tubules were clearly distributed, spermatogenic cells of various developmental stages were visible from the basal surface to the luminal surface, and there were a large number of mature sperm; the seminiferous epithelium of the testicular tissue of the mice in the diabetic model control group was significantly thinned, the seminiferous tubules were severely atrophied, cavities were visible in the cavity, and only a small number of mature sperm were present; after the administration of cordycepin preparation, the testicular tissue morphology of the mice was significantly restored, the seminiferous epithelium became thicker, the cavity had cells of various layers, and a large number of mature sperm were visible.

[0178] PAS staining results of mouse testis Fig.18 As shown, the normal control group (i.e., blank group) had neatly arranged spermatogenic cells at all levels, while the diabetic model control group had fewer spermatogenic cells at all levels, loosely arranged, and few elongated sperm. Administration of cordycepin preparation reversed the damage to the testicular tissue of mice caused by diabetes.

[0179] 6. Effects of different weight proportions of cordycepin preparations on complications of retinal damage in type 2 diabetes

[0180] Mouse retina H&E staining Fig.19 As shown, the inner limiting membrane of the retinal tissue of mice in the normal control group (i.e., blank group) was intact, no capillary endothelial cells were embedded, the ganglion cell layer cells were tightly arranged in a single layer, no ganglion cells were lost, and the remaining layers were neatly arranged with clear structures; the retinal ganglion cells of mice in the diabetic model control group were visibly reduced, and the retinal thickness became thinner. Cordycepin preparation treatment can initially improve the retinal damage caused by diabetes.

[0181] The present invention provides a cordycepin preparation and its preparation method and application ideas and methods. There are many methods and ways to implement the technical solution. The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the protection scope of the present invention. All components not specified in this embodiment can be implemented by existing technologies.

Claims

1. A cordycepin preparation, characterized in that: It is composed of the following components in parts by weight: 1-80 parts of cordycepin; Salidroside 1-100 parts; 1-100 parts of gastrodin.

2. The cordycepin preparation according to claim 1, characterized in that It is composed of the following components in parts by weight: 10-40 parts of cordycepin; Salidroside 40-80 parts; 40-80 parts of gastrodin.

3. The cordycepin preparation according to claim 2, characterized in that It is composed of the following components in parts by weight: Cordycepin 20 parts; Salidroside 60 parts; 60 parts of gastrodin.

4. The cordycepin preparation according to claim 3, characterized in that It is composed of the following components in parts by weight: Cordycepin 20mg; Salidroside 60mg; Gastrodin 60mg.

5. The cordycepin preparation according to claim 1, characterized in that The cordycepin has a purity greater than 90%; the mass content of cordyceps polysaccharide in the cordycepin is greater than 6%.

6. The cordycepin preparation according to claim 1, characterized in that The salidroside has a purity greater than 98%.

7. The cordycepin preparation according to claim 1, characterized in that The gastrodin has a purity of more than 98%.

8. The cordycepin preparation according to claim 1, characterized in that The dosage form of the cordycepin preparation is any one of powder, capsule, pill, granule, tablet and oral liquid preparation.

9. The method for preparing the cordycepin preparation according to claim 1, characterized in that: After cordycepin, salidroside and gastrodin are mixed, one or more pharmaceutically acceptable excipients are added, and the cordycepin preparation is prepared by a conventional preparation method of a pharmaceutical preparation.

10. Use of the cordycepin preparation according to claim 1 in the preparation of products for improving complications of type 2 diabetes.